Bayer AG-backed research from Economist Enterprise is calling for self-care to be treated as an integrated part of healthcare delivery rather than an informal substitute for doctors, pharmacies and health facilities. Published on July 23, 2026, the report argues that supported self-care could widen access, encourage earlier intervention and release capacity within overstretched health systems, provided people receive reliable information, affordable products and clear routes to professional care.
The report, titled “Making self-care work: integrating self-care into health systems,” cites an estimate that self-care practices could generate approximately $179 billion in annual economic benefits. That figure is important, but it should not be mistaken for a new economic result generated directly by the Economist Enterprise study. The report was based on desk research and expert interviews, while the headline estimate originated from earlier Global Self-Care Federation modeling.
This distinction defines how the findings should be interpreted. The publication is a health-policy and implementation analysis rather than a clinical trial, prospective health-system evaluation or independently controlled assessment of particular medicines, digital platforms or patient outcomes. Its value lies in identifying the conditions under which self-care may support healthcare systems, not in proving that every self-care intervention will improve outcomes or reduce costs.
Why does the Economist Enterprise report insist that self-care must remain connected to formal healthcare?
The central argument is that self-care works best as part of a supported healthcare pathway. It should allow individuals to manage appropriate everyday health needs while preserving access to pharmacists, primary-care professionals, diagnostic services and hospitals when symptoms become more serious, persistent or uncertain.
That principle sounds straightforward, yet it addresses one of the most consequential risks in the self-care debate. When policymakers promote self-management mainly as a way to cut appointments or contain expenditure, responsibility can quietly move from institutions to individuals. People may then be expected to interpret symptoms, judge product suitability and decide when escalation is necessary without sufficient information or professional support.
Economist Enterprise instead frames self-care as complementary capacity. Reliable health information could help people respond earlier to minor conditions, maintain preventive behaviours or monitor established health risks. Clear referral pathways would then ensure that self-management does not become delayed diagnosis, inappropriate medication use or prolonged reliance on an intervention that is not working.
The World Health Organization uses a similarly broad definition, covering the ability of individuals, families and communities to promote health, prevent disease, maintain wellbeing and cope with illness, with or without support from health workers. It also states that self-care should provide additional options within an enabling environment rather than replace healthcare systems.
What does the $179 billion self-care estimate measure, and how cautiously should it be used?
The $179 billion figure is likely to attract the most attention because it translates self-care into a scale that finance ministries, payers and health-system executives can immediately understand. However, the number is a projected economic estimate, not an observed saving collected from national health budgets following implementation of the new report’s recommendations.
The Global Self-Care Federation’s earlier research estimated that existing practices were saving healthcare systems nearly $120 billion annually. Its modeling projected that the value could rise to approximately $179 billion by 2030 as access and appropriate use expanded. The original work covered 155 countries and used literature review, economic modeling, healthcare-access groupings and projected consumption of non-prescription products.
Such modeling can help demonstrate the possible order of magnitude, but it necessarily depends on assumptions about which consultations can be avoided, how products are used, what professional time is released and whether self-management produces equivalent or better outcomes. Savings could be overstated when inappropriate self-treatment delays necessary care, while benefits could be understated when prevention produces longer-term gains that are difficult to capture.
The strongest policy use of the estimate is therefore not to promise a guaranteed $179 billion dividend. It is to justify better measurement. Governments considering self-care strategies will need country-specific data on avoided consultations, hospital utilisation, treatment delays, medication-related harm, patient expenditure, health outcomes and the distribution of benefits across different population groups.
Why will health literacy and affordability decide whether self-care expands access or inequality?
A product may be available without a prescription and still remain inaccessible in practice. Price, geography, disability, language, literacy, internet connectivity and trust can all influence whether people can understand and use self-care options appropriately.
Health literacy is particularly important because the modern self-care environment extends far beyond medicine labels. Individuals may encounter symptom checkers, wearable-device alerts, social-media advice, online pharmacies, nutritional claims and direct-to-consumer health services before speaking to a professional. More choice can increase autonomy, but it also increases the amount of information a person must evaluate.
The burden should not rest entirely on the individual. Health systems, manufacturers, pharmacies and digital-platform operators need to make instructions understandable, identify limitations clearly and provide escalation guidance that people can act upon. Information must also account for cultural and linguistic differences rather than assuming that one standardised message will work across every population.
Affordability creates a second tension. Self-care may reduce travel, waiting time and consultation costs, but it can also increase direct household expenditure when products, devices or digital subscriptions are excluded from public coverage. A strategy presented as patient empowerment could therefore widen inequality when wealthier groups gain convenient preventive support while lower-income populations are left with underfunded services and additional out-of-pocket costs.
Economist Enterprise identifies affordable access, appropriate financing and culturally relevant support as essential safeguards. Its analysis also warns that policy ambitions will have limited value unless responsibilities for implementation and accountability are clearly assigned.
How should health systems govern digital tools, non-prescription medicines and self-monitoring?
Self-care spans interventions with very different risk profiles. Healthy lifestyle information, an established non-prescription medicine, a connected blood-pressure monitor and an artificial intelligence symptom checker cannot be governed as though they present identical evidence, privacy and safety questions.
Non-prescription medicines require clear labeling, pharmacovigilance, contraindication information and safeguards against inappropriate duration or combination use. Pharmacists can provide an important bridge by helping consumers select appropriate products, identify medicine interactions and recognise symptoms that require medical evaluation.
Digital self-care tools introduce additional questions. Health systems must consider whether a tool has been clinically validated, what population was used for testing, whether results generalise across demographic groups and what happens when the software produces a false reassurance or unnecessary alarm. Tools that collect sensitive data also require privacy, cybersecurity and consent protections.
Integration becomes more demanding when home-generated information is expected to enter clinical workflows. Providers need to know which data are reliable, how alerts should be prioritised, who is accountable for responding and whether additional monitoring creates more workload than it removes. A thousand automated notifications are not a capacity solution if clinicians must manually investigate every one of them.
Regulation must consequently be proportionate to intended use and risk. Educational wellness content should not be presented as diagnosis. A self-monitoring device should not be assumed to improve patient outcomes merely because it records measurements accurately. An algorithm that offers symptom guidance should not be described as a substitute for clinical judgment unless its regulatory status and evidence genuinely support autonomous use.
What would meaningful self-care implementation look like beyond policy statements?
The report identifies governance, equitable access and stronger measurement as the three broad requirements for moving from endorsement to implementation. The difficult work begins beneath those headings.
Governance requires named responsibility. Health ministries may set policy, but medicines regulators, digital-health authorities, professional bodies, insurers, pharmacy networks and healthcare providers all influence how self-care operates. Without coordination, patients may receive contradictory advice or encounter gaps between consumer products and clinical services.
Health systems also need explicit referral protocols. People should be able to understand which symptoms can reasonably be managed at home, how long self-treatment should continue and which warning signs require professional attention. Pharmacists, community health workers and digital platforms could support these pathways, but only when their roles and escalation responsibilities are clearly defined.
Economist Enterprise points to Germany’s use of green prescriptions, through which physicians can recommend appropriate non-prescription products, and Indonesia’s GERMAS healthy-living movement as examples of self-care being connected with wider health policy. These programmes illustrate possible integration mechanisms, although their inclusion in the report should not be read as proof that the models will deliver identical outcomes in other health systems.
Implementation should ultimately be assessed using outcomes rather than campaign reach. Useful measures could include timely escalation, medication-related incidents, avoidable appointments, emergency admissions, patient confidence, household spending and differences in access between socioeconomic groups. Counting app downloads or educational leaflets would reveal activity, but not whether care became safer or more equitable.
Why is the self-care agenda commercially relevant to Bayer Consumer Health?
Bayer AG supported the Economist Enterprise research and has a direct commercial interest in the wider adoption of responsible self-care. Its Consumer Health division sells products across digestive health, dermatology, pain and cardiovascular care, nutritionals, and allergy and cold categories.
The division generated €5.802 billion in sales during 2025, broadly unchanged on a currency-adjusted and portfolio-adjusted basis. Growth in digestive health, dermatology and pain and cardiovascular products was offset by weaker nutritionals and allergy and cold performance, particularly amid challenging conditions in North America and Asia-Pacific.
That context makes the policy debate strategically relevant. Wider recognition of pharmacies, non-prescription medicines and preventive consumer-health products could expand category participation and support new product-switch or distribution opportunities. Better health literacy could also improve confidence in appropriately selected products.
Commercial alignment does not invalidate the report, but it should shape how its claims are classified. The publication is supported by a major consumer-health manufacturer and draws partly on research from the Global Self-Care Federation, an industry body. Its recommendations should therefore be evaluated alongside regulatory evidence, independent health-economic research and country-level implementation data.
For Bayer, the report is better understood as a long-term category-development initiative than as a near-term financial catalyst. The commercial opportunity depends on governments accepting self-care as part of healthcare infrastructure while maintaining rigorous standards for evidence, safety, affordability and truthful product communication.
What will determine whether self-care relieves healthcare pressure without transferring risk?
The future of integrated self-care will depend less on whether governments formally recognise the concept and more on whether they build the systems required to support it. The decisive tests will include trusted information, risk-appropriate regulation, affordable access, pharmacist and clinician involvement, reliable escalation routes and measurable accountability.
Self-care can plausibly release professional capacity when people are equipped to manage suitable needs confidently and safely. It can also improve prevention and patient participation. However, those benefits weaken when self-care becomes a euphemism for reduced access, unchecked commercialisation or unsupported responsibility.
The Economist Enterprise report captures that tension effectively. Its most valuable conclusion is not the headline economic figure, but the recognition that self-care cannot operate as healthcare’s unmonitored waiting room. It must function as a connected entry point, with professionals and institutions still accountable for ensuring that people know when self-management is appropriate and when formal care must take over.
